Osimertinib Approved as Adjuvant Therapy for NSCLC with Certain EGFR Mutations

First Therapeutic Approval in 16 years for MPM

FDA Perspectives on the Use of Liquid Biopsy in NSCLC

Funding Opportunities for Innovative Multidisciplinary Cancer Research Teams

FDA Approves Pralsetinib for RET Fusion–Positive NSCLC

Huge Strides for Liquid Biopsy Assays with Two FDA Approvals

Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic

Oncology Trials Could Benefit From Increased Data on Tobacco Use

Changing E-Cigarette Technology Leads to Increased Complexity and Confusion—IASLC Statement Aims for Clarity

Breaking News Briefs

Breaking News Briefs

Breaking News Briefs